Medtech Insight is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Yielding what industry analysts deem to be around a 50% share of the US Pap smear market, cervical cell screening technology company AutoCyte will acquire automated Pap smear developer NeoPath in a stock swap valued at about $101mm, based on AutoCyte's $7.35 pre-announcement 10-day average trailing price. The price represents a (pr)46% premium to the $3.97 10-day trailing average for NeoPath common.
In Vitro Diagnostics
Payment Includes Stock
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?